华森制药
(002907)
| 流通市值：49.87亿 | | | 总市值：61.43亿 |
| 流通股本：3.39亿 | | | 总股本：4.18亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 413,550,709.65 | 211,846,896.79 | 827,144,563.24 | 625,912,023.87 |
| 营业收入 | 413,550,709.65 | 211,846,896.79 | 827,144,563.24 | 625,912,023.87 |
| 二、营业总成本 | 349,874,529.4 | 177,299,368.93 | 767,774,090.85 | 557,825,404.58 |
| 营业成本 | 168,472,990.15 | 84,877,415.77 | 352,473,143.2 | 261,503,492.55 |
| 税金及附加 | 6,549,923.6 | 1,932,667.4 | 13,263,030.97 | 8,669,328.67 |
| 销售费用 | 114,776,537.61 | 59,793,167.38 | 254,701,445.04 | 191,208,013.54 |
| 管理费用 | 29,692,379.15 | 13,962,662.33 | 63,921,731.09 | 43,339,930.2 |
| 研发费用 | 33,214,812.56 | 19,485,969.17 | 89,763,263.67 | 59,240,206.24 |
| 财务费用 | -2,832,113.67 | -2,752,513.12 | -6,348,523.12 | -6,135,566.62 |
| 其中:利息费用 | 363,353.56 | 70,526.75 | 139,708.52 | -290,221.62 |
| 其中:利息收入 | 3,211,571.98 | 2,148,524.5 | 6,512,669.91 | 6,072,928.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,270,498.82 | 569,139.3 | 1,417,619.96 | 1,160,617.85 |
| 加:投资收益 | 1,734,617.83 | 1,091,051.02 | 8,276,482.1 | 16,901,273.28 |
| 资产处置收益 | - | - | 10,245,671.69 | 8,563,232.58 |
| 资产减值损失(新) | -583,194.64 | -3,533.11 | -1,490,077.76 | -407,492.6 |
| 信用减值损失(新) | -3,589,870.31 | -1,361,325.01 | -454,296.83 | -1,133,910.25 |
| 其他收益 | 5,503,241.85 | 2,796,663.14 | 16,597,362.58 | 12,825,780.32 |
| 四、营业利润 | 68,011,473.8 | 37,639,523.2 | 93,963,234.13 | 105,996,120.47 |
| 加:营业外收入 | 117,723.84 | 12,666.16 | 441,976.96 | 157,672.86 |
| 减:营业外支出 | 332,838.91 | 51,081.99 | 16,948,672.92 | 16,607,704.05 |
| 五、利润总额 | 67,796,358.73 | 37,601,107.37 | 77,456,538.17 | 89,546,089.28 |
| 减:所得税费用 | 11,842,687.72 | 8,693,299.4 | 22,246,059.79 | 21,627,956.11 |
| 六、净利润 | 55,953,671.01 | 28,907,807.97 | 55,210,478.38 | 67,918,133.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 55,953,671.01 | 28,907,807.97 | 55,210,478.38 | 67,918,133.17 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 62,984,195.42 | 32,790,793.15 | 65,086,781.36 | 72,455,605.89 |
| 少数股东损益 | -7,030,524.41 | -3,882,985.18 | -9,876,302.98 | -4,537,472.72 |
| 扣除非经常损益后的净利润 | 56,421,793.99 | 29,032,183.76 | 46,862,738.79 | 52,203,509.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.08 | 0.16 | 0.17 |
| (二)稀释每股收益 | 0.15 | 0.08 | 0.16 | 0.17 |
| 八、其他综合收益 | -415,472.41 | -65,466.58 | -394,361.81 | -49,336.4 |
| 归属于母公司股东的其他综合收益 | -415,472.41 | -65,466.58 | -394,361.81 | -49,336.4 |
| 九、综合收益总额 | 55,538,198.6 | 28,842,341.39 | 54,816,116.57 | 67,868,796.77 |
| 归属于母公司股东的综合收益总额 | 62,568,723.01 | 32,725,326.57 | 64,692,419.55 | 72,406,269.49 |
| 归属于少数股东的综合收益总额 | -7,030,524.41 | -3,882,985.18 | -9,876,302.98 | -4,537,472.72 |
| 公告日期 | 2026-08-21 | 2026-04-30 | 2026-04-24 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |